$CELC
Celcuity Inc.

2020 Q4 Form 10-Q Financial Statement

#000165495420012025 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $440.0K $520.0K $380.0K
YoY Change 10.0% 36.84% 0.0%
% of Gross Profit
Research & Development $2.110M $1.963M $1.712M
YoY Change 40.67% 14.67% 7.04%
% of Gross Profit
Depreciation & Amortization $100.0K $100.0K $90.00K
YoY Change 11.11% 11.11% 43.29%
% of Gross Profit
Operating Expenses $2.550M $2.480M $2.091M
YoY Change 34.21% 18.59% 5.84%
Operating Profit -$2.480M -$2.091M
YoY Change 18.59% 5.84%
Interest Expense $0.00 $28.00 $39.00
YoY Change -100.0% -28.21% -40.0%
% of Operating Profit
Other Income/Expense, Net $5.777K $107.1K
YoY Change -94.6% 2.22%
Pretax Income -$2.550M -$2.474M -$1.984M
YoY Change 40.88% 24.7% 6.05%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.550M -$2.474M -$1.984M
YoY Change 40.88% 24.7% 6.05%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$248.1K -$240.5K -$193.4K
COMMON SHARES
Basic Shares Outstanding 10.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.64M $13.70M $20.45M
YoY Change -37.89% -33.01% -10.15%
Cash & Equivalents $11.64M $13.70M $16.27M
Short-Term Investments $4.180M
Other Short-Term Assets $340.0K $120.0K $160.0K
YoY Change 6.25% -25.0% -60.0%
Inventory
Prepaid Expenses $317.0K $103.6K
Receivables
Other Receivables $190.0K $190.0K
Total Short-Term Assets $12.17M $14.01M $20.61M
YoY Change -36.8% -32.01% -11.01%
LONG-TERM ASSETS
Property, Plant & Equipment $558.9K $626.3K $1.130M
YoY Change -32.95% -44.58% 38.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $789.8K $902.0K $1.130M
YoY Change -23.35% -20.18% -76.13%
TOTAL ASSETS
Total Short-Term Assets $12.17M $14.01M $20.61M
Total Long-Term Assets $789.8K $902.0K $1.130M
Total Assets $12.96M $14.91M $21.74M
YoY Change -36.11% -31.4% -22.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $217.4K $83.13K $200.0K
YoY Change 52.25% -58.44% 12.56%
Accrued Expenses $774.6K $756.9K $710.0K
YoY Change 32.57% 6.6% -8.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $1.185M $1.035M $910.0K
YoY Change 30.06% 13.76% -5.27%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $10.00K $20.00K
YoY Change 0.0% -50.0% 0.0%
Other Long-Term Liabilities $60.00K $110.0K $100.0K
YoY Change 0.0% 10.0%
Total Long-Term Liabilities $70.00K $120.0K $120.0K
YoY Change 0.0% 0.0% 500.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.185M $1.035M $910.0K
Total Long-Term Liabilities $70.00K $120.0K $120.0K
Total Liabilities $1.254M $1.152M $1.030M
YoY Change 27.59% 11.84% 4.9%
SHAREHOLDERS EQUITY
Retained Earnings -$26.32M -$23.77M
YoY Change 56.24%
Common Stock $10.30K $10.29K
YoY Change 0.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.70M $13.76M $20.71M
YoY Change
Total Liabilities & Shareholders Equity $12.96M $14.91M $21.74M
YoY Change -36.11% -31.4% -22.06%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$2.550M -$2.474M -$1.984M
YoY Change 40.88% 24.7% 6.05%
Depreciation, Depletion And Amortization $100.0K $100.0K $90.00K
YoY Change 11.11% 11.11% 43.29%
Cash From Operating Activities -$2.110M -$1.650M -$1.470M
YoY Change 23.39% 12.24% -17.42%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$10.00K -$170.0K
YoY Change -66.67% -94.12% 54.55%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $3.000M
YoY Change -100.0% -100.0% 20.97%
Cash From Investing Activities -$10.00K -$10.00K $2.830M
YoY Change -100.24% -100.35% 18.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 60.00K -70.00K 0.000
YoY Change 100.0% -100.0%
NET CHANGE
Cash From Operating Activities -2.110M -1.650M -1.470M
Cash From Investing Activities -10.00K -10.00K 2.830M
Cash From Financing Activities 60.00K -70.00K 0.000
Net Change In Cash -2.060M -1.730M 1.360M
YoY Change -183.74% -227.21% 130.51%
FREE CASH FLOW
Cash From Operating Activities -$2.110M -$1.650M -$1.470M
Capital Expenditures -$10.00K -$10.00K -$170.0K
Free Cash Flow -$2.100M -$1.640M -$1.300M
YoY Change 25.0% 26.15% -22.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10296998 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13696387 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18735002 USD
CY2019Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
22009 USD
CY2019Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
28743 USD
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
190000 USD
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
274600 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
19250354 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
833463 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
196983 USD
CY2019Q4 us-gaap Assets
Assets
20280800 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
142773 USD
CY2020Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
5799 USD
CY2019Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
5769 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
189400 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
756873 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
83130 USD
CY2020Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
22009 USD
CY2020Q3 us-gaap Deferred Costs Current
DeferredCostsCurrent
0 USD
CY2020Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
190000 USD
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
103610 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
14012006 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
626271 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
275696 USD
CY2020Q3 us-gaap Assets
Assets
14913973 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1035202 USD
CY2019Q4 us-gaap Liabilities
Liabilities
983229 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
10254 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20280800 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-5907537 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
28 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
39 USD
us-gaap Interest Expense
InterestExpense
93 USD
us-gaap Interest Expense
InterestExpense
123 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5805 USD
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
107100 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
81639 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
81546 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
357321 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5777 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
107061 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
178466 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
584319 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
911327 USD
CY2020Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
9756 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
14109 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
107040 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
57793 USD
CY2020Q3 us-gaap Liabilities
Liabilities
1151998 USD
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10289253 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10253988 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
10289 USD
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
37522374 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
36134723 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23770688 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16847406 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
13761975 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
19297571 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14913973 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1962610 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1711597 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5576250 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4772286 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
517465 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
379718 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1428578 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1135251 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
2480075 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
2091315 USD
us-gaap Operating Expenses
OperatingExpenses
7004828 USD
us-gaap Operating Expenses
OperatingExpenses
5907537 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2480075 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2091315 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7004828 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
357198 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2474298 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1984254 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6923282 USD
CY2019Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
303244 USD
CY2019Q3 celc Exercise Of Common Stock Options Net Of Shares Withheld For Exercise Price Amount
ExerciseOfCommonStockOptionsNetOfSharesWithheldForExercisePriceAmount
0 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-1984254 USD
us-gaap Share Based Compensation
ShareBasedCompensation
680134 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
20712429 USD
us-gaap Net Income Loss
NetIncomeLoss
-6923282 USD
us-gaap Net Income Loss
NetIncomeLoss
-5550339 USD
us-gaap Depreciation
Depreciation
287701 USD
us-gaap Depreciation
Depreciation
245689 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1336789 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5550339 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2474298 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-1984254 USD
us-gaap Net Income Loss
NetIncomeLoss
-6923282 USD
us-gaap Net Income Loss
NetIncomeLoss
-5550339 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10273567 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10239957 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10262636 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10217443 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
19297571 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
464649 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2246995 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
17515225 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
423193 USD
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
23897 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
154142 USD
CY2020Q2 celc Issuance Costs Associated With Atm Offering
IssuanceCostsAssociatedWithAtmOffering
-52110 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2201989 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
15862358 USD
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
448947 USD
CY2020Q3 celc Issuance Costs Associated With Atm Offering
IssuanceCostsAssociatedWithAtmOffering
-75032 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2474298 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
13761975 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
25349611 USD
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
184645 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
174957 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1845908 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
23863305 USD
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
192246 USD
CY2019Q2 celc Exercise Of Common Stock Options Net Of Shares Withheld For Exercise Price Amount
ExerciseOfCommonStockOptionsNetOfSharesWithheldForExercisePriceAmount
0 USD
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
58065 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1720177 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
22393439 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
29082 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
170990 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
144743 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-64657 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
102977 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
172554 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
70571 USD
celc Increase Decrease In Non Cash Operating Lease Expense
IncreaseDecreaseInNonCashOperatingLeaseExpense
-18533 USD
celc Increase Decrease In Non Cash Operating Lease Expense
IncreaseDecreaseInNonCashOperatingLeaseExpense
-17810 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5038438 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4294953 USD
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0 USD
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
4745000 USD
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
-75494 USD
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
-352490 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-75494 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4392510 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
174957 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
23897 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
58065 USD
celc Gross Proceeds From An Atm Offering
GrossProceedsFromAnAtmOffering
154142 USD
celc Gross Proceeds From An Atm Offering
GrossProceedsFromAnAtmOffering
0 USD
celc Payments For Registration Statement Costs
PaymentsForRegistrationStatementCosts
-98399 USD
celc Payments For Registration Statement Costs
PaymentsForRegistrationStatementCosts
-1300 USD
celc Payments For Capital Leases
PaymentsForCapitalLeases
-4323 USD
celc Payments For Capital Leases
PaymentsForCapitalLeases
-4293 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75317 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
227429 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5038615 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
324986 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18735002 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15944609 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13696387 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16269595 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
7714 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
2005 USD
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span style="text-decoration:underline">Accounting Estimates</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Management uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span style="text-decoration:underline">Risks and Uncertainties</span></strong><span style="text-decoration:underline"> </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</p>
CY2019Q1 celc Operating Lease Right Of Use Assets
OperatingLeaseRightOfUseAssets
356539 USD
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
404931 USD
CY2019Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
63875 USD
CY2019Q1 us-gaap Prepaid Rent
PrepaidRent
15483 USD
us-gaap Lease Cost
LeaseCost
195498 USD
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
197211 USD
celc Operating Lease Weighted Average Remaining Leases Term1
OperatingLeaseWeightedAverageRemainingLeasesTerm1
P1Y7M6D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.40 pure
celc Finance Lease Weighted Average Remaining Leases Term1
FinanceLeaseWeightedAverageRemainingLeasesTerm1
P2Y8M12D
CY2020Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.10 pure
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
43974 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
126100 USD
CY2020Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1447 USD
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
4340 USD
CY2020Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
28 USD
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
93 USD
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
20300 USD
us-gaap Variable Lease Cost
VariableLeaseCost
64965 USD
CY2020Q3 us-gaap Lease Cost
LeaseCost
65749 USD
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
46003 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
209598 USD
CY2020Q3 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
28 USD
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
93 USD
CY2020Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1444 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
4323 USD
CY2020Q3 celc Cash Paid For Operating And Finance Leases
CashPaidForOperatingAndFinanceLeases
47475 USD
celc Cash Paid For Operating And Finance Leases
CashPaidForOperatingAndFinanceLeases
214014 USD
CY2019 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
50000 USD
CY2018 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
200000 USD
CY2017 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
350000 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
238146 shares
CY2020Q3 celc Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Remainder Of Fiscal Year
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear
412433 USD
CY2020Q3 celc Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Two Years
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears
1299933 USD
CY2020Q3 celc Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Three Years
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears
997358 USD
CY2020Q3 celc Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Four Years
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears
644448 USD
CY2020Q3 celc Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Five Years
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears
145405 USD
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3499577 USD
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
448947 USD
CY2019Q3 us-gaap Share Based Compensation
ShareBasedCompensation
303244 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1336789 USD
us-gaap Share Based Compensation
ShareBasedCompensation
680134 USD

Files In Submission

Name View Source Status
0001654954-20-012025-index-headers.html Edgar Link pending
0001654954-20-012025-index.html Edgar Link pending
0001654954-20-012025.txt Edgar Link pending
0001654954-20-012025-xbrl.zip Edgar Link pending
celc-20200930.xsd Edgar Link pending
celc-20200930_cal.xml Edgar Link unprocessable
celc-20200930_def.xml Edgar Link unprocessable
celc-20200930_lab.xml Edgar Link unprocessable
celc-20200930_pre.xml Edgar Link unprocessable
celc_10q.htm Edgar Link pending
celc_10q_htm.xml Edgar Link completed
celc_ex311.htm Edgar Link pending
celc_ex312.htm Edgar Link pending
celc_ex321.htm Edgar Link pending
celc_ex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending